Fate pulls the plug on a cell therapy project after Phase II

Fate Therapeutics ($FATE) is dumping its lead clinical program, moving forward with an early-stage cell therapy the company believes has more commercial promise. The San Diego company is abandoning clinical development of ProHema, a treatment for hematological malignancies that is derived from umbilical cord blood. In a Phase II trial, ProHema demonstrated improved engraftment rates compared to standard hematopoietic cell transplantation, Fate said, but the company is shifting its focus to a preclinical project called ProTmune, which is designed to prevent graft-versus-host disease. Fate is now planning to enroll a Phase I/II clinical trial of ProTmune next year. The company's shares fell about 7% on the news Monday. More

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.